Related Experiment Video
Updated: Aug 8, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Omeprazole-induced hepatotoxicity? A case report
1Gerontopharmacology Unit, Hôpital de Gériatrie, CH-1226 Geneva, Switzerland. christe-caroline@diogenes.hcuge.ch
Omeprazole, a common medication, can rarely cause severe liver injury (hepatotoxicity). This case report highlights a patient who experienced liver damage after long-term omeprazole use, emphasizing the need for vigilance.
Area of Science:
- Hepatology
- Pharmacovigilance
- Internal Medicine
Background:
- Proton pump inhibitors like omeprazole are widely used for acid-related gastrointestinal disorders.
- While generally safe, rare adverse drug reactions (ADRs) can occur, necessitating ongoing monitoring.
- Hepatotoxicity is a potential, albeit uncommon, side effect associated with various medications.
Purpose of the Study:
- To report a case of severe symptomatic hepatocellular liver injury potentially induced by long-term omeprazole use.
- To contribute to the understanding of rare adverse drug reactions associated with omeprazole.
- To underscore the importance of considering drug-induced liver injury in patients presenting with unexplained hepatitis.
Main Methods:
- A case report of an 85-year-old male patient with a history of ischemic heart disease.
- Detailed observation of liver enzyme levels (AST, ALT, AP) before, during, and after omeprazole treatment and re-challenge.
- Review of existing literature and drug regulatory agency databases for reported cases of omeprazole-induced liver injury.
Main Results:
- The patient developed severe symptomatic hepatocellular liver injury with significantly elevated liver enzymes during long-term omeprazole therapy.
- Discontinuation of omeprazole led to normalization of liver enzymes within 12 days.
- Re-exposure to omeprazole resulted in a recurrence of elevated liver enzymes, further supporting a causal link.
- While clinical studies report minimal liver enzyme elevations in 1-5% of cases, this case demonstrates severe hepatotoxicity.
Conclusions:
- Hepatitis is a rare but possible complication of omeprazole treatment, as suggested by this case and international reports.
- The Swiss Drug Regulatory Agency and WHO Data Base have documented cases of omeprazole-associated liver injury, including cholestatic hepatitis and hepatic failure.
- This case emphasizes the importance of considering omeprazole as a potential cause of severe liver injury, especially with prolonged use or in susceptible individuals.
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Drug Toxicity: Risk factors

